AZEDRA
About AZEDRA
Founded in 2006, AZEDRA operates in the healthcare sector with a focus on treatments for rare neuroendocrine tumors. Therapy services targeting pheochromocytoma and paraganglioma are delivered to patients. These interventions address specific disease challenges through specialized protocols. The companys online presence is maintained via azedra.com, supporting access to information and resources. Operations emphasize therapeutic solutions without specified geographic limitations.
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of AZEDRA
Detailed funding history for AZEDRA
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in AZEDRA
AZEDRA has secured backing from 1 investor. Prominent investors backing the company include Progenics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Imaging compounds & targeted radiotherapies to detect and treat prostate cancer.
|
Locked | Locked | Locked |
Investor details for AZEDRA
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AZEDRA
Investment portfolio details for AZEDRA
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AZEDRA
Detailed financials for AZEDRA
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Azedra Comparisons
Peer comparison for AZEDRA
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AZEDRA
Detailed competitors of AZEDRA
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Azedra
Complete news archive for AZEDRA
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AZEDRA
AZEDRA was founded in 2006.
Founded in 2006, AZEDRA operates in the healthcare sector with a focus on treatments for rare neuroendocrine tumors. Therapy services targeting pheochromocytoma and paraganglioma are delivered to patients. These interventions address specific disease challenges through specialized protocols. The companys online presence is maintained via azedra.com, supporting access to information and resources. Operations emphasize therapeutic solutions without specified geographic limitations.
AZEDRA has 1 investor. Key investors include Progenics.